Bharat Biotech partners with CEPI to develop ‘variant-proof’ COVID-19 vaccine1 min read . Updated: 10 May 2022, 07:42 PM IST
- The international multidisciplinary consortium will constitute of Bharat Biotech, the University of Sydney and ExcellGene SA, Switzerland
NEW DELHI : Hyderabad based pharma giant Bharat Biotech has partnered with an international multidisciplinary consortium and is all set to receive a funding of US $19.3 million for the the development of a ‘variant-proof’ coronavirus vaccine candidate that will provide protection against SARS-Cov-2 variants and other beta coronaviruses.
Select your Category